UNSPSC 51385901: Darbufelone

This classification denotes a cyclooxygenase inhibitor with the molecular formula C18H24N2O2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 72H8H6K34C, chemically known as 5-((z)-3,5-di-tert-butyl-4-hydroxybenzylidene)-2-imino-4-thiazolidinone. but generally known as darbufelone, which bears US NIH Compound Identifier 6444826. European Medicines Agency schedules Darbufelone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB26843.

UNSPSC 51385901 Darbufelone, a Commodity-tier code, does not align with the recent state and local procurement activity tagged under it. The three most recent opportunities posted under this code involve naloxone and drug-deactivation systems (Seminole County, Florida), direct-to-manufacturer pharmacy prescriptions (Texas Health and Human Services Commission), and multi-source generic pharmaceuticals and OTC products (Minnesota Multistate Cooperative Purchasing Alliance)—none of which concern darbufelone, a specific pharmaceutical compound. State and local buyers using this code appear to be sourcing broadly across pharmaceutical and health-care products rather than procuring darbufelone specifically.

The issuing bodies include county health authorities, state health agencies, and multi-state cooperative purchasing alliances. Seminole County posted an IFB on June 30, 2026 due July 26, 2023 for naloxone and drug-deactivation systems with quarterly deliveries and FEMA-potential funding. The Texas HHS Commission issued an RFI on April 3, 2026 to assess vendor capabilities for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager channels. The Minnesota Department of Administration, administering MMCAP, released an RFP posted January 20, 2026 due March 26, 2026 for generic multi-source pharmaceuticals and OTC products distributed across state and local facilities in Minnesota and Oregon through three authorized wholesalers. Activity concentrates in Florida, Texas, and the upper Midwest, though the code's current tagging suggests misalignment between the taxonomy and what is actually being bought. Firms pursuing work under this code should investigate whether the Darbufelone designation reflects ongoing procurement need or represents a data-classification artifact.